JP2004507440A - 細菌に対するフルオロキノロン化合物の使用法 - Google Patents
細菌に対するフルオロキノロン化合物の使用法 Download PDFInfo
- Publication number
- JP2004507440A JP2004507440A JP2001519909A JP2001519909A JP2004507440A JP 2004507440 A JP2004507440 A JP 2004507440A JP 2001519909 A JP2001519909 A JP 2001519909A JP 2001519909 A JP2001519909 A JP 2001519909A JP 2004507440 A JP2004507440 A JP 2004507440A
- Authority
- JP
- Japan
- Prior art keywords
- gemifloxacin
- mic
- quinolone
- ciprofloxacin
- resistant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title abstract description 119
- 229940124307 fluoroquinolone Drugs 0.000 title description 64
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical class C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 abstract description 437
- 238000000034 method Methods 0.000 abstract description 309
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract description 197
- 244000052616 bacterial pathogen Species 0.000 abstract description 72
- 239000003242 anti bacterial agent Substances 0.000 abstract description 24
- 229940088710 antibiotic agent Drugs 0.000 abstract description 17
- 229960003170 gemifloxacin Drugs 0.000 description 602
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 410
- 229960003405 ciprofloxacin Drugs 0.000 description 205
- 230000000694 effects Effects 0.000 description 193
- -1 3-aminomethyl-4-methoxyiminopyrrolidin-1-yl Chemical group 0.000 description 191
- 244000052769 pathogen Species 0.000 description 187
- 230000000845 anti-microbial effect Effects 0.000 description 162
- 239000004599 antimicrobial Substances 0.000 description 142
- 229960000497 trovafloxacin Drugs 0.000 description 118
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 118
- 241000193998 Streptococcus pneumoniae Species 0.000 description 116
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 116
- 239000000203 mixture Substances 0.000 description 113
- 238000012360 testing method Methods 0.000 description 108
- 230000001374 post-anti-biotic effect Effects 0.000 description 105
- 230000001717 pathogenic effect Effects 0.000 description 100
- 150000007660 quinolones Chemical class 0.000 description 95
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 92
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 86
- 208000015181 infectious disease Diseases 0.000 description 84
- 229960003376 levofloxacin Drugs 0.000 description 84
- 241000606768 Haemophilus influenzae Species 0.000 description 72
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 70
- 229940049954 penicillin Drugs 0.000 description 62
- 229930182555 Penicillin Natural products 0.000 description 61
- AIJTTZAVMXIJGM-UHFFFAOYSA-N Grepafloxacin Chemical compound C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 AIJTTZAVMXIJGM-UHFFFAOYSA-N 0.000 description 59
- 229960000642 grepafloxacin Drugs 0.000 description 59
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 55
- 241000589248 Legionella Species 0.000 description 55
- 229960001699 ofloxacin Drugs 0.000 description 55
- 241000124008 Mammalia Species 0.000 description 54
- 239000003814 drug Substances 0.000 description 52
- 241000589291 Acinetobacter Species 0.000 description 50
- 241000605894 Porphyromonas Species 0.000 description 50
- 230000000844 anti-bacterial effect Effects 0.000 description 50
- 239000003795 chemical substances by application Substances 0.000 description 49
- 238000011282 treatment Methods 0.000 description 49
- 208000035143 Bacterial infection Diseases 0.000 description 48
- 208000022362 bacterial infectious disease Diseases 0.000 description 48
- 241000194017 Streptococcus Species 0.000 description 47
- 229960003276 erythromycin Drugs 0.000 description 46
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 45
- 229960004954 sparfloxacin Drugs 0.000 description 45
- 229920001817 Agar Polymers 0.000 description 43
- 208000007764 Legionnaires' Disease Diseases 0.000 description 43
- 239000008272 agar Substances 0.000 description 43
- 229940079593 drug Drugs 0.000 description 43
- 230000004060 metabolic process Effects 0.000 description 43
- 230000035945 sensitivity Effects 0.000 description 43
- 241001647372 Chlamydia pneumoniae Species 0.000 description 41
- 229940047650 haemophilus influenzae Drugs 0.000 description 41
- 238000010790 dilution Methods 0.000 description 40
- 239000012895 dilution Substances 0.000 description 40
- 238000000338 in vitro Methods 0.000 description 40
- 241000204031 Mycoplasma Species 0.000 description 39
- 229960004099 azithromycin Drugs 0.000 description 39
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 39
- 150000001875 compounds Chemical class 0.000 description 35
- 239000002054 inoculum Substances 0.000 description 35
- 230000001580 bacterial effect Effects 0.000 description 34
- 229960002626 clarithromycin Drugs 0.000 description 34
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 34
- 241000191992 Peptostreptococcus Species 0.000 description 33
- 238000003556 assay Methods 0.000 description 33
- 239000002609 medium Substances 0.000 description 32
- 229960003702 moxifloxacin Drugs 0.000 description 32
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 32
- 241000588724 Escherichia coli Species 0.000 description 29
- 241000191967 Staphylococcus aureus Species 0.000 description 29
- 229960001668 cefuroxime Drugs 0.000 description 28
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 28
- 241000894007 species Species 0.000 description 28
- 241000605909 Fusobacterium Species 0.000 description 26
- 229960003022 amoxicillin Drugs 0.000 description 25
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 25
- 241000588655 Moraxella catarrhalis Species 0.000 description 24
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 23
- 239000004098 Tetracycline Substances 0.000 description 23
- 230000001105 regulatory effect Effects 0.000 description 23
- 235000019364 tetracycline Nutrition 0.000 description 23
- 150000003522 tetracyclines Chemical class 0.000 description 23
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 22
- 229940023064 escherichia coli Drugs 0.000 description 22
- 229960002180 tetracycline Drugs 0.000 description 22
- 229930101283 tetracycline Natural products 0.000 description 22
- 241000700159 Rattus Species 0.000 description 21
- 241000191963 Staphylococcus epidermidis Species 0.000 description 21
- 238000002814 agar dilution Methods 0.000 description 21
- 230000003389 potentiating effect Effects 0.000 description 20
- 241000606125 Bacteroides Species 0.000 description 18
- 241000193163 Clostridioides difficile Species 0.000 description 18
- 206010057190 Respiratory tract infections Diseases 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 18
- 108010041052 DNA Topoisomerase IV Proteins 0.000 description 17
- 241000589242 Legionella pneumophila Species 0.000 description 17
- 241000193403 Clostridium Species 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 16
- 210000004086 maxillary sinus Anatomy 0.000 description 16
- 238000003908 quality control method Methods 0.000 description 16
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 16
- 201000009906 Meningitis Diseases 0.000 description 15
- 241000204051 Mycoplasma genitalium Species 0.000 description 15
- 238000002512 chemotherapy Methods 0.000 description 15
- 239000003120 macrolide antibiotic agent Substances 0.000 description 15
- 230000000241 respiratory effect Effects 0.000 description 15
- 241000606124 Bacteroides fragilis Species 0.000 description 14
- 241000605986 Fusobacterium nucleatum Species 0.000 description 14
- 206010027202 Meningitis bacterial Diseases 0.000 description 14
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 14
- 206010035664 Pneumonia Diseases 0.000 description 14
- 241000295644 Staphylococcaceae Species 0.000 description 14
- 241000191940 Staphylococcus Species 0.000 description 14
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 14
- 201000009904 bacterial meningitis Diseases 0.000 description 14
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 13
- 241000194032 Enterococcus faecalis Species 0.000 description 13
- 108010059993 Vancomycin Proteins 0.000 description 13
- 229940032049 enterococcus faecalis Drugs 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 244000000058 gram-negative pathogen Species 0.000 description 13
- 230000035772 mutation Effects 0.000 description 13
- 210000002345 respiratory system Anatomy 0.000 description 13
- 229960003165 vancomycin Drugs 0.000 description 13
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 13
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 13
- 241000186046 Actinomyces Species 0.000 description 12
- 241000588747 Klebsiella pneumoniae Species 0.000 description 12
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 12
- 229960000723 ampicillin Drugs 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 241000588626 Acinetobacter baumannii Species 0.000 description 11
- 241000588921 Enterobacteriaceae Species 0.000 description 11
- 241001494479 Pecora Species 0.000 description 11
- 241000607720 Serratia Species 0.000 description 11
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 11
- 229960001225 rifampicin Drugs 0.000 description 11
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 11
- 241000607142 Salmonella Species 0.000 description 10
- 229960002227 clindamycin Drugs 0.000 description 10
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 244000005700 microbiome Species 0.000 description 10
- 229940068196 placebo Drugs 0.000 description 10
- 239000000902 placebo Substances 0.000 description 10
- 238000001228 spectrum Methods 0.000 description 10
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 9
- 229930182566 Gentamicin Natural products 0.000 description 9
- 241000605861 Prevotella Species 0.000 description 9
- 241000588767 Proteus vulgaris Species 0.000 description 9
- 241000202921 Ureaplasma urealyticum Species 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000002550 fecal effect Effects 0.000 description 9
- 101150070420 gyrA gene Proteins 0.000 description 9
- 244000005706 microflora Species 0.000 description 9
- 229940007042 proteus vulgaris Drugs 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 9
- 150000003952 β-lactams Chemical class 0.000 description 9
- 241000588625 Acinetobacter sp. Species 0.000 description 8
- 241000606208 Campylobacter gracilis Species 0.000 description 8
- 241000193468 Clostridium perfringens Species 0.000 description 8
- 108090000204 Dipeptidase 1 Proteins 0.000 description 8
- 206010018612 Gonorrhoea Diseases 0.000 description 8
- 244000158996 Hedysarum boreale Species 0.000 description 8
- 241000588772 Morganella morganii Species 0.000 description 8
- 241000202952 Mycoplasma fermentans Species 0.000 description 8
- 241000193996 Streptococcus pyogenes Species 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 241001148470 aerobic bacillus Species 0.000 description 8
- 102000006635 beta-lactamase Human genes 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 8
- JIYMVSQRGZEYAX-CWUUNJJBSA-N gemifloxacin mesylate Chemical compound CS(O)(=O)=O.C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 JIYMVSQRGZEYAX-CWUUNJJBSA-N 0.000 description 8
- 229960002518 gentamicin Drugs 0.000 description 8
- 244000000059 gram-positive pathogen Species 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 229940041033 macrolides Drugs 0.000 description 8
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 8
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 7
- 241000305071 Enterobacterales Species 0.000 description 7
- 241000194031 Enterococcus faecium Species 0.000 description 7
- 241000192016 Finegoldia magna Species 0.000 description 7
- 241000588621 Moraxella Species 0.000 description 7
- 241000204048 Mycoplasma hominis Species 0.000 description 7
- 241000605862 Porphyromonas gingivalis Species 0.000 description 7
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 7
- 241001312524 Streptococcus viridans Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 229960004261 cefotaxime Drugs 0.000 description 7
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229960003923 gatifloxacin Drugs 0.000 description 7
- 229960001151 gemifloxacin mesylate Drugs 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 229940076266 morganella morganii Drugs 0.000 description 7
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 7
- 229960000210 nalidixic acid Drugs 0.000 description 7
- 230000036515 potency Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000006150 trypticase soy agar Substances 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 6
- 241001541756 Acinetobacter calcoaceticus subsp. anitratus Species 0.000 description 6
- 241000147019 Enterobacter sp. Species 0.000 description 6
- 241000589282 Fluoribacter dumoffii Species 0.000 description 6
- 241000605952 Fusobacterium necrophorum Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 241000204003 Mycoplasmatales Species 0.000 description 6
- 241000192035 Peptostreptococcus anaerobius Species 0.000 description 6
- 241001148530 Porphyromonas circumdentaria Species 0.000 description 6
- 241000588769 Proteus <enterobacteria> Species 0.000 description 6
- 241000588778 Providencia stuartii Species 0.000 description 6
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 6
- 238000002815 broth microdilution Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- JHAXGSQISYDXFP-UHFFFAOYSA-N 3-fluoro-1h-1,8-naphthyridin-2-one Chemical compound C1=CN=C2NC(=O)C(F)=CC2=C1 JHAXGSQISYDXFP-UHFFFAOYSA-N 0.000 description 5
- 241001232615 Acinetobacter baumannii ATCC 19606 = CIP 70.34 = JCM 6841 Species 0.000 description 5
- 241001135518 Acinetobacter lwoffii Species 0.000 description 5
- 229930186147 Cephalosporin Natural products 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108010054814 DNA Gyrase Proteins 0.000 description 5
- 241000588697 Enterobacter cloacae Species 0.000 description 5
- 241000194033 Enterococcus Species 0.000 description 5
- 241000192125 Firmicutes Species 0.000 description 5
- 241001303074 Fusobacterium naviforme Species 0.000 description 5
- 241000605978 Fusobacterium russii Species 0.000 description 5
- 241000588915 Klebsiella aerogenes Species 0.000 description 5
- 241000588754 Klebsiella sp. Species 0.000 description 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 5
- 206010033078 Otitis media Diseases 0.000 description 5
- 241000192013 Peptoniphilus asaccharolyticus Species 0.000 description 5
- 241001135209 Prevotella denticola Species 0.000 description 5
- 241001135221 Prevotella intermedia Species 0.000 description 5
- 241000588770 Proteus mirabilis Species 0.000 description 5
- 241000607768 Shigella Species 0.000 description 5
- 206010041925 Staphylococcal infections Diseases 0.000 description 5
- 241000202898 Ureaplasma Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 229940124587 cephalosporin Drugs 0.000 description 5
- 150000001780 cephalosporins Chemical class 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940047766 co-trimoxazole Drugs 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000003113 dilution method Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229940092559 enterobacter aerogenes Drugs 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 208000001786 gonorrhea Diseases 0.000 description 5
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 5
- 229960002422 lomefloxacin Drugs 0.000 description 5
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 5
- 229960003085 meticillin Drugs 0.000 description 5
- 229940056360 penicillin g Drugs 0.000 description 5
- 229940074571 peptostreptococcus anaerobius Drugs 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 4
- 206010001076 Acute sinusitis Diseases 0.000 description 4
- 241000588807 Bordetella Species 0.000 description 4
- 241000589513 Burkholderia cepacia Species 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000605974 Fusobacterium necrogenes Species 0.000 description 4
- 241000605991 Fusobacterium ulcerans Species 0.000 description 4
- 241000606841 Haemophilus sp. Species 0.000 description 4
- 241001464887 Parvimonas micra Species 0.000 description 4
- 241001135241 Porphyromonas macacae Species 0.000 description 4
- 241001135223 Prevotella melaninogenica Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 241000122971 Stenotrophomonas Species 0.000 description 4
- 241000193985 Streptococcus agalactiae Species 0.000 description 4
- 241000589262 Tatlockia micdadei Species 0.000 description 4
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000006161 blood agar Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 229960002129 cefixime Drugs 0.000 description 4
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 4
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000417 fungicide Substances 0.000 description 4
- 101150013736 gyrB gene Proteins 0.000 description 4
- 229960002182 imipenem Drugs 0.000 description 4
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 4
- 229940115932 legionella pneumophila Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229940037201 oris Drugs 0.000 description 4
- 101150012629 parE gene Proteins 0.000 description 4
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 201000009890 sinusitis Diseases 0.000 description 4
- 229960003177 sitafloxacin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 3
- BSIMZHVOQZIAOY-SCSAIBSYSA-N 1-carbapenem-3-carboxylic acid Chemical compound OC(=O)C1=CC[C@@H]2CC(=O)N12 BSIMZHVOQZIAOY-SCSAIBSYSA-N 0.000 description 3
- 241001464890 Anaerococcus prevotii Species 0.000 description 3
- 241000589562 Brucella Species 0.000 description 3
- 206010009137 Chronic sinusitis Diseases 0.000 description 3
- 241000588919 Citrobacter freundii Species 0.000 description 3
- 241001112695 Clostridiales Species 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- 241000605908 Fusobacterium gonidiaformans Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000002768 Kirby-Bauer method Methods 0.000 description 3
- 241000588749 Klebsiella oxytoca Species 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 241000588650 Neisseria meningitidis Species 0.000 description 3
- 208000012868 Overgrowth Diseases 0.000 description 3
- 241000878522 Porphyromonas crevioricanis Species 0.000 description 3
- 241001300940 Porphyromonas sp. Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 241001148134 Veillonella Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 241000186561 [Clostridium] clostridioforme Species 0.000 description 3
- 241000193462 [Clostridium] innocuum Species 0.000 description 3
- 230000003497 anti-pneumococcal effect Effects 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 229910052788 barium Inorganic materials 0.000 description 3
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 229960004755 ceftriaxone Drugs 0.000 description 3
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229960003722 doxycycline Drugs 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000013100 final test Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000000855 fungicidal effect Effects 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960001180 norfloxacin Drugs 0.000 description 3
- 239000006916 nutrient agar Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 102220104078 rs77026017 Human genes 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- IKYGJSBKPPIKJK-JDKVAZDPSA-N (6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[[6,8-difluoro-1-(2-fluoroethyl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carbonyl]oxymethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1COC(=O)C(C(C1=CC=2F)=O)=CN(CCF)C1=C(F)C=2N1CCN(C)CC1 IKYGJSBKPPIKJK-JDKVAZDPSA-N 0.000 description 2
- QKDHBVNJCZBTMR-LLVKDONJSA-N (R)-temafloxacin Chemical compound C1CN[C@H](C)CN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F QKDHBVNJCZBTMR-LLVKDONJSA-N 0.000 description 2
- FNKLCGHPPNAPBJ-UHFFFAOYSA-N 1-cyclopropyl-7-(2,6-dimethylpyridin-4-yl)-6-fluoro-4-oxoquinoline-3-carboxylic acid Chemical compound CC1=NC(C)=CC(C=2C(=CC=3C(=O)C(C(O)=O)=CN(C=3C=2)C2CC2)F)=C1 FNKLCGHPPNAPBJ-UHFFFAOYSA-N 0.000 description 2
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 description 2
- MUKSDTOOLRNSIO-QMMMGPOBSA-N 7-[(3s)-3-aminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid Chemical compound C1[C@@H](N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 MUKSDTOOLRNSIO-QMMMGPOBSA-N 0.000 description 2
- 241000186041 Actinomyces israelii Species 0.000 description 2
- 241000722954 Anaerobiospirillum succiniciproducens Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241001135237 Bacteroides heparinolyticus Species 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- 241000588779 Bordetella bronchiseptica Species 0.000 description 2
- 241000588780 Bordetella parapertussis Species 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 241000606177 Campylobacter ureolyticus Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 241000589244 Fluoribacter bozemanae Species 0.000 description 2
- 241000605956 Fusobacterium mortiferum Species 0.000 description 2
- 241000959640 Fusobacterium sp. Species 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000606766 Haemophilus parainfluenzae Species 0.000 description 2
- 241000589268 Legionella sp. Species 0.000 description 2
- 208000004023 Legionellosis Diseases 0.000 description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241001430197 Mollicutes Species 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 108010087702 Penicillinase Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000035109 Pneumococcal Infections Diseases 0.000 description 2
- 241001509390 Porphyromonas canoris Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000607714 Serratia sp. Species 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003570 air Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 238000011203 antimicrobial therapy Methods 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000002902 bimodal effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 2
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940025294 hemin Drugs 0.000 description 2
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000022760 infectious otitis media Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 101150110811 parC gene Proteins 0.000 description 2
- 229950009506 penicillinase Drugs 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 102220223196 rs146238336 Human genes 0.000 description 2
- 229960005404 sulfamethoxazole Drugs 0.000 description 2
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- PPKJUHVNTMYXOD-GKSTYDNOSA-N synercid Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)CC2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-GKSTYDNOSA-N 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960004576 temafloxacin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000010610 time kill assay Methods 0.000 description 2
- 229950008187 tosufloxacin Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- NLEPLDKPYLYCSY-UHFFFAOYSA-N 2-fluoroquinoline Chemical compound C1=CC=CC2=NC(F)=CC=C21 NLEPLDKPYLYCSY-UHFFFAOYSA-N 0.000 description 1
- HETSDWRDICBRSQ-UHFFFAOYSA-N 3h-quinolin-4-one Chemical class C1=CC=C2C(=O)CC=NC2=C1 HETSDWRDICBRSQ-UHFFFAOYSA-N 0.000 description 1
- LAXQWNGETIROHJ-UHFFFAOYSA-N 6-fluoro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)C=CC2=CC(F)=CN=C21 LAXQWNGETIROHJ-UHFFFAOYSA-N 0.000 description 1
- RRCVQLJMMWUIGG-UHFFFAOYSA-N 6h-quinolin-5-one Chemical compound C1=CC=C2C(=O)CC=CC2=N1 RRCVQLJMMWUIGG-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000034950 Acinetobacter Infections Diseases 0.000 description 1
- 208000029329 Acinetobacter infectious disease Diseases 0.000 description 1
- 241000186066 Actinomyces odontolyticus Species 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000722955 Anaerobiospirillum Species 0.000 description 1
- 241000786447 Anaerobiospirillum thomasii Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 241000423333 Bacteroides fragilis NCTC 9343 Species 0.000 description 1
- 241001221145 Bacteroides pyogenes Species 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 241001495172 Bilophila wadsworthia Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241001508395 Burkholderia sp. Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 240000006563 Curcuma aeruginosa Species 0.000 description 1
- 101710116957 D-alanyl-D-alanine carboxypeptidase Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 241000943303 Enterococcus faecalis ATCC 29212 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001058146 Erium Species 0.000 description 1
- 241000186588 Erysipelatoclostridium ramosum Species 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 235000015164 Iris germanica var. florentina Nutrition 0.000 description 1
- 240000004101 Iris pallida Species 0.000 description 1
- 235000015265 Iris pallida Nutrition 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 206010024179 Legionella infections Diseases 0.000 description 1
- 241000937819 Legionella pneumophila serogroup 1 Species 0.000 description 1
- 241001135523 Legionella wadsworthii Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 241001135743 Mycoplasma penetrans Species 0.000 description 1
- 241000202944 Mycoplasma sp. Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102220509145 PDZ domain-containing protein 11_S81Y_mutation Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241001135211 Porphyromonas asaccharolytica Species 0.000 description 1
- 241001135215 Prevotella bivia Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 230000027151 SOS response Effects 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241001147693 Staphylococcus sp. Species 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 201000008837 acute maxillary sinusitis Diseases 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- GHPGOEFPKIHBNM-UHFFFAOYSA-N antimony(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Sb+3].[Sb+3] GHPGOEFPKIHBNM-UHFFFAOYSA-N 0.000 description 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003578 bacterial chromosome Anatomy 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000007330 chocolate agar Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 201000006918 chronic maxillary sinusitis Diseases 0.000 description 1
- 229940088516 cipro Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- QGPKADBNRMWEQR-UHFFFAOYSA-N clinafloxacin Chemical compound C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl QGPKADBNRMWEQR-UHFFFAOYSA-N 0.000 description 1
- 229950001320 clinafloxacin Drugs 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- FHYWAOQGXIZAAF-GHXIOONMSA-N desacetylcefotaxime Chemical compound N([C@@H]1C(N2C(=C(CO)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 FHYWAOQGXIZAAF-GHXIOONMSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- HEDOODBJFVUQMS-UHFFFAOYSA-N n-[2-(5-methoxy-1h-indol-3-yl)ethyl]-n-methylpropan-2-amine Chemical group COC1=CC=C2NC=C(CCN(C)C(C)C)C2=C1 HEDOODBJFVUQMS-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229940124588 oral cephalosporin Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
- 229960004236 pefloxacin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- VXGYRCVTBHVXMZ-UHFFFAOYSA-N quinoline-6-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CC=C21 VXGYRCVTBHVXMZ-UHFFFAOYSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 229940052337 quinupristin/dalfopristin Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000006965 reversible inhibition Effects 0.000 description 1
- 102200118420 rs11570255 Human genes 0.000 description 1
- 102200075749 rs397514044 Human genes 0.000 description 1
- 102220265217 rs770735510 Human genes 0.000 description 1
- 102220126945 rs771101156 Human genes 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031003 streptococcus viridans group Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 206010051250 ureteritis Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (36)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15183799P | 1999-09-01 | 1999-09-01 | |
| US15196099P | 1999-09-01 | 1999-09-01 | |
| US15191799P | 1999-09-01 | 1999-09-01 | |
| US15183499P | 1999-09-01 | 1999-09-01 | |
| US15183699P | 1999-09-01 | 1999-09-01 | |
| US15183599P | 1999-09-01 | 1999-09-01 | |
| US15411599P | 1999-09-14 | 1999-09-14 | |
| US15388499P | 1999-09-14 | 1999-09-14 | |
| US15538399P | 1999-09-22 | 1999-09-22 | |
| US15534799P | 1999-09-22 | 1999-09-22 | |
| US15515099P | 1999-09-22 | 1999-09-22 | |
| US15538199P | 1999-09-22 | 1999-09-22 | |
| US15536099P | 1999-09-22 | 1999-09-22 | |
| US15539599P | 1999-09-22 | 1999-09-22 | |
| US15534899P | 1999-09-22 | 1999-09-22 | |
| US15534499P | 1999-09-22 | 1999-09-22 | |
| US15538499P | 1999-09-22 | 1999-09-22 | |
| US15514999P | 1999-09-22 | 1999-09-22 | |
| US15539299P | 1999-09-22 | 1999-09-22 | |
| US15514899P | 1999-09-22 | 1999-09-22 | |
| US15539399P | 1999-09-22 | 1999-09-22 | |
| US15535899P | 1999-09-22 | 1999-09-22 | |
| US15534699P | 1999-09-22 | 1999-09-22 | |
| US15538099P | 1999-09-22 | 1999-09-22 | |
| US15537999P | 1999-09-22 | 1999-09-22 | |
| US15533899P | 1999-09-22 | 1999-09-22 | |
| US15534999P | 1999-09-22 | 1999-09-22 | |
| US15539199P | 1999-09-22 | 1999-09-22 | |
| US15539499P | 1999-09-22 | 1999-09-22 | |
| US15535999P | 1999-09-22 | 1999-09-22 | |
| US15534099P | 1999-09-22 | 1999-09-22 | |
| US15538299P | 1999-09-22 | 1999-09-22 | |
| US15595799P | 1999-09-24 | 1999-09-24 | |
| US15586999P | 1999-09-24 | 1999-09-24 | |
| US15586899P | 1999-09-24 | 1999-09-24 | |
| PCT/US2000/023883 WO2001015695A1 (en) | 1999-09-01 | 2000-08-31 | Methods of use of fluoroquinolone compounds against bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004507440A true JP2004507440A (ja) | 2004-03-11 |
| JP2004507440A5 JP2004507440A5 (enExample) | 2007-10-18 |
Family
ID=27586941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001519909A Pending JP2004507440A (ja) | 1999-09-01 | 2000-08-31 | 細菌に対するフルオロキノロン化合物の使用法 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1401440A4 (enExample) |
| JP (1) | JP2004507440A (enExample) |
| AU (1) | AU6947900A (enExample) |
| WO (1) | WO2001015695A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9920919D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel compound |
| GB9920917D0 (en) | 1999-09-03 | 1999-11-10 | Sb Pharmco Inc | Novel process |
| ES2314082T3 (es) | 2001-08-02 | 2009-03-16 | Lg Life Sciences Limited | Procedimientos para la produccion de derivados amino protegidos de 4-aminometilenpirrolidin-3-ona, gemifloxacina y sus sales. |
| KR100517638B1 (ko) | 2002-04-08 | 2005-09-28 | 주식회사 엘지생명과학 | 게미플록사신 산염의 새로운 제조방법 |
-
2000
- 2000-08-31 AU AU69479/00A patent/AU6947900A/en not_active Abandoned
- 2000-08-31 JP JP2001519909A patent/JP2004507440A/ja active Pending
- 2000-08-31 WO PCT/US2000/023883 patent/WO2001015695A1/en not_active Ceased
- 2000-08-31 EP EP00993844A patent/EP1401440A4/en not_active Withdrawn
Non-Patent Citations (8)
| Title |
|---|
| JPN6011000084, ＡＮＴＩＭＩＣＲＯＢＩＡＬ ＡＧＥＮＴＳ ＡＮＤ ＣＨＥＭＯＴＨＥＲＡＰＹ， ＡＭＥＲＩＣＡＮ ＳＯＣＩＥＴＹ ＦＯＲ ＭＩＣＲＯＢＩＯＬＯＧＹ， ｖｏｌ． ４０， ｎｏ． ６， １９９６， ｐａｇｅ * |
| JPN6011000091, ＤＩＡＧＮＯＳＴＩＣ ＭＩＣＲＯＢＩＯＬＯＧＹ ＡＮＤ ＩＮＦＥＣＴＩＯＵＳ ＤＩＳＥＡＳＥＳ， ｖｏｌ． ３３， ｎｏ． ２， Ｆｅｂｒｕａｒｙ １９９９， ｐａｇｅｓ ８７−９１ * |
| JPN6011000097, ＣＵＲＲＥＮＴ ＯＰＩＮＩＯＮ ＩＮ ＡＮＴＩ−ＩＮＦＥＣＴＩＶＥ ＩＮＶＥＳＴＩＧＡＴＩＯＮＡＬ ＤＲＵＧＳ， ｖｏｌ． １， ｎｏ． ４， Ｓｅｐ１９９９， ｐａｇｅｓ ４９３−５００ * |
| JPN7011000011, Ｊ． ＡＮＴＩＭＩＣＲＯＢ． ＣＨＥＭＯＴＨＥＲ． ｖｏｌ． ４４， ｎｏ． ＳＵＰＰＬ． Ａ， Ｊｕｌｙ １９９９， ｐａｇｅ １４７ ，Ｐ４８８ * |
| JPN7011000012, Ｊ． ＡＮＴＩＭＩＣＲＯＢ． ＣＨＥＭＯＴＨＥＲ． ｖｏｌ． ４４， ｎｏ． ＳＵＰＰＬ． Ａ， Ｊｕｌｙ １９９９， ｐａｇｅ １４６，Ｐ４８２ * |
| JPN7011000013, Ｊ． ＡＮＴＩＭＩＣＲＯＢ． ＣＨＥＭＯＴＨＥＲ． ｖｏｌ． ４４， ｎｏ． ＳＵＰＰＬ． Ａ， Ｊｕｌｙ １９９９， ｐａｇｅ １４０，Ｐ４５２ * |
| JPN7011000014, Ｊ． ＡＮＴＩＭＩＣＲＯＢ． ＣＨＥＭＯＴＨＥＲ．， ｖｏｌ． ４４， ｎｏ． ＳＵＰＰＬ Ａ， Ｊｕｌｙ １９９９ ， ｐａｇｅ １４８，Ｐ４９２ * |
| JPN7011000015, ＡＮＴＩＭＩＣＲＯＢＩＡＬ ＡＧＥＮＴＳ ＡＮＤ ＣＨＥＭＯＴＨＥＲＡＰＹ， ｖｏｌ． ４１， ｎｏ． １， １９９７ ， ｐａｇｅｓ ２０４−２１１ * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001015695A1 (en) | 2001-03-08 |
| AU6947900A (en) | 2001-03-26 |
| EP1401440A4 (en) | 2006-07-05 |
| EP1401440A1 (en) | 2004-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harwell et al. | The drug-resistant pneumococcus: clinical relevance, therapy, and prevention | |
| Appelbaum et al. | Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 US centers | |
| Pankuch et al. | Susceptibilities of 428 gram-positive and-negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin | |
| Goldstein | Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents | |
| Eliopoulos | Quinolone resistance mechanisms in pneumococci | |
| Davies et al. | Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity | |
| Collignon et al. | Drug‐resistant Streptococcus pneumoniae: the beginning of the end for many antibiotics? | |
| JP2017533945A (ja) | 耐性細菌感染症の治療のための併用療法 | |
| HUE027373T2 (hu) | Kezelési eljárások oritavancin egyszeri dózisainak alkalmazásával | |
| Nicolle | Best pharmacological practice: urinary tract infections | |
| Davies et al. | The quinolones in chronic bronchitis | |
| WO2001000209A1 (en) | Methods of use of fluoroquinolone compounds against bacteria | |
| Blondeau et al. | Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents | |
| Yzerman et al. | Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus. | |
| Castanheira et al. | Changing antimicrobial susceptibility patterns among Streptococcus pneumoniae and Haemophilus influenzae from Brazil: report from the SENTRY Antimicrobial Surveillance Program (1998–2004) | |
| Finch | The role of new quinolones in the treatment of respiratory tract infections | |
| US7595328B2 (en) | Methods of use of quinolone compounds against pneumococcal and Haemophilus bacteria | |
| US9913854B2 (en) | Methods and compositions for reducing the proliferation of gram positive bacteria | |
| WO2001015695A1 (en) | Methods of use of fluoroquinolone compounds against bacteria | |
| Barry | In vitro activity of the quinolones and related compounds | |
| JP2017055716A (ja) | 多剤耐性菌スクリーニング用プレート、多剤耐性菌の検出方法、多剤耐性菌検出キットおよび多剤耐性菌スクリーニング用液体培地 | |
| Farca et al. | In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals | |
| Walz et al. | Excellent activity of newer quinolones on Legionella pneumophila in J774 macrophages | |
| Thomson et al. | In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance | |
| EP1561465A2 (en) | Methods of use of fluoroquinolone compounds against bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070828 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070828 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110111 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110705 |